The New Wave of Anti-Trans Legislation Sure Looks a Lot Like Eugenics
By Evan Urquhart,
Slate
| 03. 03. 2021
State-level bills around women’s sports and adolescent medical care would seem to share a common goal.
Photo by Sharon McCutcheon on Unsplash
A huge wave of anti-transgender legislation is coursing through statehouses in the early months of 2021. Bills that have been introduced (often with the same or similar language across states) follow one of two models: Some prohibit trans youth from participating in female-designated sports programs, while others seek to criminalize the provision of age-appropriate, trans-affirming medical care to minors. If you’re wondering why legislators (and the advocacy groups that feed them policy ideas) are focused on these particular issues, it may be useful to consider the concept of eugenics. Yes, it’s a heavy word, evoking some of the more horrific historical misuses of “science,” but think about it: These are bills aimed at cleansing society of the “wrong” sort of people as soon as their difference makes itself visible, and promoting the right sort in their place.
Trans people have been talking about anti-trans measures in the context of eugenics for a while, but the most prominent voice linking the current GOP-led efforts with eugenics is ACLU lawyer (and sometime Slate contributor)...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...